Innate Pharma ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
4analysts covering
FY EPS (est.)
-$0.10next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| H2 2026 Monalizumab PACIFIC-9 Phase 3 Data Readout | 31 Dec 2026 |
| H2 2026 Lacutamab TELLOMAK-3 Phase 3 Trial Planned Initiation | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly25.4MTarget: Sufficient non-dilutive financing to initiate Phase 3 TELLOMAK-3 trial
Quarterly Revenue Quarterly2.6MTarget: Revenue from collaboration and licensing agreements (AstraZeneca and Sanofi)
Watch Items
- Monalizumab PACIFIC-9 Phase 3 Trial Data ReadoutTrigger: H2 2026Action: Evaluate high-level efficacy and safety results in unresectable Stage III NSCLC in collaboration with AstraZeneca.
- Lacutamab TELLOMAK-3 Phase 3 Trial InitiationTrigger: H2 2026Action: Secure non-dilutive financing options (pharma partnering or royalty structures) to initiate the confirmatory trial.
- IPH4502 (Nectin-4 ADC) Phase 1 Dose Escalation CompletionTrigger: Nearing completion of enrollment in dose escalation and cohort enrichmentAction: Analyze preliminary anti-tumor activity and safety profile to determine recommended Phase 2 dose.
Research as of 20 Jun 2026